上海医药拟公开挂牌转让中美施贵宝30%股权

Core Viewpoint - Shanghai Pharmaceuticals plans to transfer its 30% stake in the subsidiary China-U.S. Shanghai Bristol-Myers Squibb Pharmaceutical Co., Ltd. through a public listing, with a minimum transfer price of 1.023 billion yuan [1] Group 1: Company Actions - The company will no longer hold any equity in China-U.S. Shanghai Bristol-Myers Squibb after the transaction is completed [1] - The transfer price will be determined based on the results of the public listing, following necessary state-owned asset evaluation procedures [1] Group 2: Financial Impact - The transaction is not expected to have a significant impact on the company's normal operations and financial status [1] - The move is aimed at protecting state-owned asset rights and maximizing asset value, aligning with the interests of the company and all shareholders [1]